---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-043009"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:21:11.268157+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ensysce completes $1.7M convertible note financing; second closing of $1.133M

## Summary
- Total gross proceeds of $1.7M from senior secured convertible notes and warrants; second closing on Nov 28/29, 2023 added $1.133M (net).
- Notes convertible at $1.5675/share, 6% interest, 6-month term; monthly redemption begins 90 days after issuance.
- Warrants to purchase up to 3.77M shares at $1.5675, exercisable for five years from issuance.
- Proceeds to fund PF614 time of onset study and regulatory milestones.
- Notes secured by all company assets and guaranteed by subsidiaries EBI OpCo and EBI.

## SEC filing metadata
- accession: 0001493152-23-043009
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/0001493152-23-043009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-043009
- JSON: https://secwatch.observer/filing/0001493152-23-043009.json
- Plain text: https://secwatch.observer/filing/0001493152-23-043009.txt

## Key facts
- Debt Financings
  Ensysce Biosciences, Inc. incurred convertible notes of aggregate principal amount of $1,224,000 with the investors at 6.0% per annum maturing six months from their respective date of issuance.
  - Instrument: convertible notes
  - Principal: aggregate principal amount of $1,224,000
  - Counterparty: the investors
  - Rate: 6.0% per annum
  - Maturity: six months from their respective date of issuance
  - Event: incurrence
  source text: the Company issued to the investors referenced above, (i) Notes in the aggregate principal amount of $1,224,000 for an aggregate purchase price of $1,133,333
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/0001493152-23-043009-index.htm
- Material Agreements
  Ensysce Biosciences, Inc. entered into Securities Purchase Agreement with investors valued at $1.7 million (effective 2023-10-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: investors
  - Value: $1.7 million
  - Effective: 2023-10-23
  source text: on October 23, 2023, Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) entered into a Securities Purchase Agreement (the “SPA”) for an aggregate financing of $1.7 million with investors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315223043009/0001493152-23-043009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.